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Summary
Background.  —  The  very  long-term  effects  of  dual  chamber  pacing  as  a  primary  treatment  for
hypertrophic  obstructive  cardiomyopathy  (HOCM)  are  poorly  known  and  controversial.
Aims. —  To  examine  the  intermediate-  and  long-term  clinical  and  haemodynamic  effects  of
permanent  dual  chamber  pacing  in  patients  presenting  with  HOCM.
Methods.  —  Between  1991  and  2007,  51  patients  (mean  age  59  ±  14  years)  presenting  with  HOCM
and New  York  Heart  Association  (NYHA)  functional  class  ≥  II  despite  optimal  medical  therapy
underwent  implantation  of  DDD  pacemakers  with  or  without  a  deﬁbrillator  and  were  followed
for 11.5  years  (range  0.4—21.8  years).
Results.  —  During  follow-up,  no  patient  underwent  myectomy  or  septal  alcohol  ablation.  NYHA
functional  class  and  other  disease  manifestations  decreased  signiﬁcantly  over  1—2  years  of
follow-up and  remained  stable  thereafter.  The  left  intraventricular  (LV)  gradient  decreased
by a  mean  of  78%  over  1—2  years,  reaching  89%  at  end  of  follow-up,  along  with  disappearance
of systolic  anterior  motion  of  the  mitral  valve.  Mean  LV  ejection  fraction  decreased  from  a  mean
of 64  ±  8%  before  pacing  to  56  ±  9%  at  end  of  follow-up  (P  =  0.05),  while  LV  end-diastolic  diam-
eter did  not  change  signiﬁcantly.  The  5-  and  10-year  actuarial  survival  rates  were  90%  and  65%,
respectively.  Among  22  deaths,  10  were  due  to  cardiovascular  and  12  to  non-cardiovascular
causes; two  patients  underwent  cardiac  transplantation  after  8  and  13  years  of  DDD  pacing,
respectively.
Abbreviations: AV, atrioventricular; HOCM, hypertrophic obstructive cardiomyopathy; ICD, implantable cardioverter deﬁbrillator;
LV, left ventricular; LVOT, left ventricular outﬂow tract; NYHA, New York Heart Association; RV, right ventricular.
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Conclusions.  —  In  this  sample  of  patients  with  HOCM,  DDD  pacing  alleviated  symptoms  and
improved haemodynamic  function  over  the  very  long  term.  The  merits  of  this  treatment  should
be revisited  in  a  controlled  trial.
© 2013  Published  by  Elsevier  Masson  SAS.
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Résumé
Contexte.  —  L’efﬁcacité  de  la  stimulation  cardiaque  double-chambre  comme  traitement  pri-
maire de  la  cardiomyopathie  hypertrophique  obstructive  (CMHO)  reste  controversée.  Les  effets
à très  long  terme  ne  sont  pas  connus.
Objectifs.  —  Décrire  les  effets  cliniques  et  hémodynamiques  à  moyen  et  à  long  terme  observés
après traitement  électrique.
Méthodes.  —  Cinquante-quatre  patients  (59  ±  14  ans)  ayant  une  CMHO  et  demeurant  symptoma-
tiques (dyspnée  NYHA  >  2)  sous  traitement  médical  optimisé,  ont  bénéﬁcié  de  l’implantation
d’un stimulateur  double-chambre  DDD  avec  ou  sans  fonction  de  déﬁbrillation  entre  1991  et
2007. Le  suivi  moyen  est  de  11,5  ans  (extrêmes  :  0,4—21,8).
Résultats.  —  Aucun  patient  n’a  eu  de  myectomie  ou  d’ablation  septale  secondaire.  Le  stade
NYHA diminue  au  cours  du  suivi  (93  %  en  stade  1—2  en  ﬁn  de  suivi  vs  43  %  avant  l’implantation,
p <  0,0001).  Angor  et  lipothymies/syncopes  diminuent  signiﬁcativement.  Le  gradient  intraven-
triculaire gauche  initialement  de  79  ±  36  mmHg  diminue  à  20  ±  24  à  trois  mois,  11  ±  15  entre  un
et deux  ans  et  8  ±  21  en  ﬁn  de  suivi  (p  <  0,0001).  Le  SAM  présent  initialement  chez  52  patients
n’est retrouvé  que  sept  fois  après  implantation  (p  <  0,0001).  La  fraction  d’éjection  tend  à  dimin-
uer en  ﬁn  de  suivi  (56  ±  9  %  vs  64  ±  8  %  ;  p  <  0,05)  alors  que  le  diamètre  télédiastolique  VG  reste
sable. Le  taux  de  survie  actuariel  est  de  90  %  à  cinq  ans  et  de  65  %  à  dix  ans.  Parmi  les  22  décès,
dix sont  de  cause  cardiovasculaire  et  12  de  cause  non  cardiovasculaire.
Conclusions.  —  Le  traitement  par  stimulation  DDD  semble  être  bénéﬁque  à  très  long  terme  sur
les symptômes  et  les  paramètres  hémodynamiques.  Il  altère  peu  ou  pas  la  fonction  systolique
VG. Ces  résultats  incitent  à  réévaluer  cette  modalité  de  traitement  dans  de  nouveaux  essais
contrôlés.
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ackground
ight  ventricular  (RV)  apical  pacing  with  preservation  of
trioventricular  (AV)  synchrony  lowers  the  left  intraventric-
lar  gradient  and  increases  cardiac  output  in  patients  with
bstructive  hypertrophic  cardiomyopathy  (HOCM)  [1,2]. A
elay  in  septal  contraction  and  long-term  ventricular  remod-
lling  have  been  suggested  as  putative  mechanisms  [3].
he  implantation  of  a  DDD  pacemaker  has  therefore  been
roposed  in  selected  patients  with  HOCM  who  remain
ymptomatic  despite  optimal  medical  management  [1,3,4].
n  contrast  with  other  non-pharmacologic  treatments  of
bstruction,  i.e.  surgical  or  alcohol  septal  reduction,  DDD
acing  has  been  evaluated  in  several  small  short  random-
zed  studies,  which  showed  no  signiﬁcant  short-term  clinical
eneﬁt  compared  with  a  placebo  effect  [5—8].  While  its
ong-term  effect  is  poorly  known,  a  few  observational  stud-
es  have  suggested  a  sustained  beneﬁt  after  4—5  years  of
acing  [9,10].  This  study  was  performed  to  evaluate  the
linical  and  haemodynamic  effects  of  this  treatment  over
he  very  long  term  in  patients  whose  symptoms  were  insuf-
ciently  alleviated  by  medical  management  alone.
ethodsnclusion criteria
e  included  in  this  study  all  patients  who,  between
une  1991  and  January  2007,  underwent  implantation  of
A
w
in  SAS.
ermanent  DDD  pacemakers,  with  or  without  an  implantable
ardioverter  deﬁbrillator  (ICD),  for  the  treatment  of  HOCM
hat  remained  symptomatic  despite  optimal  medical  man-
gement.  During  the  study  period,  short  AV  delay  DDD
acing  was  the  preferred  option  for  treating  obstruction  at
ur  institution;  eight  other  patients  had  surgical  myectomy
nd  ﬁve  had  transcatheter  septal  ablation  as  the  primary
pproach.  Inclusions  were  stopped  from  2007  to  have  a
inimum  follow-up  time  of  5  years.  The  diagnosis  of  HOCM
as  based  on  the  World  Health  Organization  criteria,  i.e.
iastolic  interventricular  septal  thickness  ≥  15  mm  (≥  13  mm
n  familial  HOCM)  measured  by  transthoracic  echocardiog-
aphy.  Intra  left  ventricular  (LV)  dynamic  obstruction  was
eﬁned  as  ≥  30  mmHg  resting  or  provoked  peak  subaortic
radient.  All  patients  were  in  New  York  Heart  Association
NYHA)  functional  class  ≥  II  and  had  undergone  unsuccessful
reatment  attempts  with  one  or  more  pharmaceutical  known
o  be  effective  in  the  treatment  of  HOCM,  including  beta-
drenergic  blockers,  verapamil/diltiazem  or  disopyramide,
r  were  intolerant  of  these  medications.  Patients  with  NYHA
unctional  class  II  had  to  report  at  least  one  other  symptom,
yncope/presyncope  or  chest  pain  to  be  included.  No  patient
ad  a primary  indication  for  permanent  cardiac  pacing  [11].
acemaker implantationll  patients  underwent  implantation  of  a  DDD  pacemaker,
ith  or  without  ICD  [12], and  with  the  ventricular  lead
mplanted  at  the  very  apex  of  the  right  ventricle.  Before
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Figure 1. Optimization of left heart atrioventricular (AV) synchrony by AV node radiofrequency modiﬁcation. Left panel: initial program-
ming. Due to short intrinsic PR interval (70 ms), the AV delay (AVD) had to be programmed at a very short value (30 ms) to achieve complete
ventricular capture from the right ventricular (RV) apex. Transmitral ﬂow shows short left ventricular (LV) ﬁlling time with no evidence of left
atrial contribution. LV outﬂow tract (LVOT) obstruction is still present with a peak gradient of 70 mmHg. Right panel: after RF modiﬁcation
of the AV node, the intrinsic PR interval is lengthened to 240 ms. Full ventricular capture is preserved while programming the AVD at 150 ms.
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on the transmitral ﬂow.
hospital  discharge,  the  AV  delay  was  systematically  pro-
grammed  at  an  ‘optimal’  value,  i.e.  the  longest  interval
associated  with  complete  ventricular  capture,  at  rest  and
during  exercise.  Radiofrequency  modiﬁcation  of  the  AV  junc-
tion  was  performed  in  patients  whose  short  spontaneous
PR  interval  precluded  the  complete  capture  of  the  ventri-
cles  (Fig.  1)  or  in  patients  with  histories  of  poorly  tolerated
recurrent  atrial  ﬁbrillation  refractory  to  antiarrhythmic  drug
therapy.  In  patients  whose  P  wave  duration  was  ≥  120  ms,  a
third  lead  was  placed  in  the  coronary  sinus  and  connected
to  a  biatrial  DDD  pacemaker  to  resynchronize  the  atria  [13].
Pharmacological  treatment  was  continued  in  all  patients.
Patient follow-up
After  device  implantation,  follow-up  data  were  collected  at
3  months,  between  1  and  2  years,  in  the  year  preceding  the
patient’s  death  or  in  2011  in  all  survivors.  The  sources  of
information  included  pacemaker  implantation  records  and
the  cardiologists’  and  primary  physicians’  progress  notes.
In  patients  whose  medical  information  was  missing,  vital
status  was  ascertained  by  consulting  the  public  records.
At  each  visit  at  the  implanting  centre,  the  patient’s  func-
tional  status  was  estimated,  based  on  NYHA  classiﬁcation
and  other  reported  symptoms,  ongoing  treatment  and  pos-
sible  interim  adverse  events  were  recorded  and  the  patients
underwent  a  physical  examination,  a  12-lead  electrocardio-
gram  recording  with  interrogation  and  veriﬁcation  of  the
o
t
A
ws indicated by the presence of ample and well-synchronized A wave
acing  system’s  proper  function  and  transthoracic  echocar-
iography  with  the  AV  interval  programmed  to  obtain  the
mallest  left  intraventricular  gradient.
tatistical analyses
ontinuous  variables  are  expressed  as  means  ±  standard
eviations  and  categorical  variables  as  counts  and  percent-
ges.  Continuous  variables  were  compared  using  repeated
easures  analysis  of  variance  and  categorical  variables  were
ompared  using  McNemar’s  Chi-square  test.  Survival  anal-
ses  were  performed  using  the  Kaplan-Meier  method  and
ompared  using  the  log-rank  test.  A  P  value  <  0.05  was  con-
idered  signiﬁcant.
esults
atient population
his  retrospective  observational  study  included  51  DDD
acemaker  recipients  who  were  followed  at  Rennes  Uni-
ersity  Medical  Centre.  The  main  baseline  characteristics
f  the  sample  are  shown  in  Table  1. Before  undergoing
evice  implantation,  41%  of  patients  had  a history  of  syncope
r  presyncope,  more  than  20%  complained  of  angina  pec-
oris  and  more  than  60%  were  in  NYHA  functional  class  >  II.
ll  but  one  patient,  who  tolerated  neither  drug  regimen,
ere  treated  with  drugs  recommended  for  the  treatment  of
376  A.  Lucon  et  al.
Table  1  Baseline  characteristics  of  the  51  recipients  of
DDD  pacemakers  or  cardioverter  deﬁbrillators.
Characteristic
Men  24  (47)
Age  (years)  59  ±  14  (24—83)
NYHA  functional  class
II  20  (39)
III  28  (54)
IV  3  (6)
Syncope  or  presyncope 21  (41)
Angina  pectoris  10  (21)
History  of  myectomy  1  (2)
Echocardiographic  measurements
Left  ventricular  ejection  fraction
(%)
63.5  ±  7.5  (44—81)
Diastolic  interventricular  septal
thickness  (mm)
18 ±  4  (13—26)
Peak  left  ventricular  outﬂow
tract  gradient  at  rest  (mmHg)
79  ±  36  (0—155)
Mitral  systolic  anterior  motion  49  (96)
Mitral  regurgitation  grade
0  2  (4)
1  21  (41)
2  23  (45)
3  5  (10)
Drug  therapy
None  1  (2)
Beta-adrenergic  blocker  36  (71)
Calcium  antagonist  14  (27)
Amiodarone  9  (18)
Disopyramide  1  (2)
Type  of  device  implanted
Dual  chamber  pacemaker  47  (92)
Dual  chamber  implantable
cardioverter  deﬁbrillator
4  (8)
Values are mean ± standard deviation (range) or number (%).
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plained  of  chest  pain  compared  with  10  patients  before
pacing  (P  <  0.0001).  Table  2  shows  the  changes  in  NYHANYHA: New York Heart Association.
ymptomatic  HOCM.  Beta-blockers  were  prescribed  to  two-
hirds  of  patients,  alone  or  in  combination  with  amiodarone
n  =  7),  a  calcium  channel  blocker  (verapamil;  n  =  3)  or
isopyramide  (n  =  1).  Verapamil  alone  was  prescribed  to
0%  of  patients.  A  single  patient  had  undergone  myectomy
2  years  before  pacemaker  implantation.
The  maximum  diastolic  interventricular  septal  thickness
anged  between  13  and  26  mm.  Systolic  anterior  motion
f  the  mitral  valve  was  present  in  49/51  patients.  In  ﬁve
atients  without  severe  LV  outﬂow  tract  (LVOT)  obstruction
nder  basal  conditions,  the  administration  of  nitroglycerine
ncreased  the  LVOT  gradient  from  a  mean  of  22  ±  9  mmHg
o  65  ±  23  mmHg.  While  nearly  all  patients  presented  with
ome  degree  of  mitral  insufﬁciency,  it  was  >  2  in  only  ﬁve
atients.rocedural data
ual  chamber  ICDs  were  implanted  in  four  patients
or  secondary  prevention  indications.  Interruption
f
b
uigure 2. Actuarial survival curve.
r  modulation  of  the  AV  junction  was  performed  before
ospital  discharge  in  four  patients,  to  optimize  AV  syn-
hrony  for  very  short  PR  intervals  during  sinus  rhythm
n  = 2)  and  for  recurrent  atrial  ﬁbrillation  with  a  rapid
entricular  rate  (n  =  2).  Biatrial  DDD  pacemakers  were
mplanted  to  resynchronize  the  atria  in  21  patients  (41%).
n  all  cases,  biatrial  pacing  was  activated  at  the  time  of
mplantation.
linical outcomes
ver  a  median  of  11.5  years  (range  0.4—21.8  years),  22
atients  died  and  two  patients  underwent  cardiac  trans-
lantation  after  8  and  13  years  of  DDD  pacing,  respectively
Fig.  2).  Among  10  patients  who  died  of  cardiovascular
auses,  four  died  suddenly,  none  had  an  ICD  implanted,
hree  died  of  end-stage  heart  failure,  two  died  of  stroke  and
ne  died  in  the  wake  of  implantation  of  a ventricular  assist
evice  as  a  bridge  to  transplantation,  after  5  years  of  pac-
ng.  The  12  remaining  patients  died  of  non-cardiovascular
auses,  8  years  on  average  after  the  implantation  of  the
DD  pacing  system.  No  patient  underwent  a supplemental
rocedure  during  follow-up,  such  as  surgical  myectomy  or
lcohol  septal  ablation  with  a  view  to  alleviate  residual  LVOT
bstruction.  The  actuarial  survival  of  the  sample  is  shown  in
ig.  2.
At  last  follow-up,  three  (7%),  24  (57%)  and  15  (36%)
atients  were  in  NYHA  functional  classes  III,  II and  I,
espectively,  compared  with  27  (53%),  21  (41%)  and  zero
atients,  respectively,  before  the  onset  of  DDD  pacing
Fig.  3).  An  increase  in  functional  capacity  was  observed
t  the  ﬁrst  follow-up,  3  months  after  the  index  implantation
rocedure.  During  follow-up,  a single  patient  complained
f  recurrent  syncope  and  presyncope  compared  with  21
efore  the  onset  of  DDD  pacing,  and  two  patients  com-unctional  class  and  major  disease  manifestations  from
efore  implantation  of  the  pacing  system  to  last  follow-
p.
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Table  2  Changes  in  New  York  Heart  Association  functional  class  and  disease  manifestations  from  before  pacing  system
implantation  to  last  follow-up.
Follow-ups  Pa
Preimplant  3  months  1—2  years  Last
(n  =  51)  (n  =  48)  (n  =  45)  (n  =  42)
NYHA  functional  class
I 0  15  (36)  16  (36)  15  (36)
II  21  (41)  26  (54)  26  (58)  24  (57)
III  27  (53)  7  (15)  3  (7)  3  (7)  <  0.0001
IV  3  (6)  0  0  0
Syncope/dizziness  21  (41) 2 (4) 2 (4)  1  (92)  <  0.001
Chest  pain 10  (21) 2 (4) 2 (4) 2 (4) <  0.001
Values are numbers (%). NYHA: New York Heart Association.
a Preimplant follow-up versus last follow-up.
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nary  sinus,  two  RV  and  one  right  atrial  leads;  connectorFigure 3. Distribution of New York Heart Association (NYHA) func-
tional classes before DDD pacing and at each follow-up.
Echocardiographic observations
The  echocardiographic  measurements  made  at  baseline
and  throughout  follow-up  are  shown  in  Table  3.  Following
implantation  of  the  pacing  system,  the  peak  LVOT  gradi-
ent  at  rest  decreased  from  a  mean  of  79  ±  36  mmHg  before
implantation  to  20  ±  24  mmHg  at  3  months,  11  ±  15  mmHg
at  1—2  years  and  8  ±  21  mmHg  at  the  ﬁnal  follow-up  after
DDD  system  implantation  (P  <  0.0001;  Fig.  4A)  in  patients
with  permanent  obstruction  at  baseline.  Systolic  anterior
motion  of  the  mitral  valve  was  present  in  6/41  patients
(15%)  at  last  follow-up,  compared  with  49/51  patients  (96%)
before  DDD  pacing  (P  <  0.0001).  When  comparing  paired
individual  measurements,  mean  LVEF  decreased  gradually
from  64  ±  8%  before  implantation  to  61  ±  7%  at  3  months,
59  ±  7%  at  1—2  years  and  56  ±  9%  at  the  last  echocardiogra-
phic  examination  (P  =  0.05;  Fig.  4B).  An  LVEF  less  than  45%
developed  in  four  patients  between  2  years  and  the  end  of
follow-up,  two  of  whom  underwent  cardiac  transplantation.
Mean  interventricular  septal  thickness  decreased  up  to  the
1—2-year  follow-up  but  this  could  not  be  conﬁrmed  at  late
follow-up  (Fig.  4C).  Paired  measurements  of  LV  end-diastolic
d
l
diameters,  available  in  21  patients,  revealed  no  signiﬁcant
hange  before  and  after  long-term  DDD  pacing;  furthermore,
he  mitral  regurgitation  grade  tended  to  decrease  during
ollow-up.
rug therapy
t  the  end  of  follow-up,  27  patients  (64%)  were  being  treated
ith  a  beta-adrenergic  blocker,  either  alone  (n  =  17;  63%)  or
ombined  with  verapamil  (n  =  7;  26%)  or  amiodarone  (n  =  5;
9%),  while  two  patients  received  the  three  classes  of  drugs.
alcium  channel  blockers  were  prescribed  to  15  patients
36%),  either  alone  (n  =  3;  20%)  or  combined  with  a  beta-
drenergic  blocker  (n  =  5;  33%)  or  amiodarone  (n  =  4;  27%).
miodarone  alone  was  prescribed  to  three  patients.
herapeutic procedures
uring  follow-up,  19  patients  underwent  radiofrequency
blation  of  AV  conduction,  to  optimize  AV  synchrony  (n  =  12)
nd  for  the  management  of  poorly  tolerated  and  recurrent
pisodes  of  atrial  ﬁbrillation  (n  =  7).  DDD  pacemakers  were
eplaced  by  a  dual  chamber  ICD  in  six  patients,  for  primary
revention  indications  (n  =  4)  and  for  the  management  of
ustained  ventricular  tachycardia  (n  =  2).
ajor treatment-related adverse events
uring  the  study  period,  procedure-  or  device-related
omplications  occurred  in  11/21  recipients  of  triple-
ead  systems  versus  7/30  recipients  of  dual-lead  systems
P  <  0.05).  In  11  patients,  complications  developed  before
ospital  discharge,  including  four  dislodgements  of  leads
hat  had  been  placed  in  the  coronary  sinus,  two  dis-
odgements  of  other  leads,  two  pericardial  effusions,  one
neumothorax  and  one  pulse  generator  pocket  infection.
omplications  that  developed  ≥  30  days  after  the  index
mplant  procedure  included:  loss  of  capture  at  three  coro-ysfunctions  of  three  triple-lead  systems;  and  two  cases  of
ead  endocarditis.  In  total,  three  infections  were  observed
uring  this  more  than  10-year  study  period:  one  early  pocket
378  A.  Lucon  et  al.
Table  3  Echocardiographic  measurements  before  and  during  DDD  pacing,  up  to  the  last  examination.
Echocardiographic  examinations  P
Preimplant  3  months  1—2  years  Last
(n  =  51)  (n  =  48)  (n  =  45)  (n  =  42)
Left  ventricular  ejection  fraction  (%)  64  ±  8  61  ±  7  59  ±  7  56  ±  9  0.05
Peak  left  intraventricular  gradient  (mmHg)  79  ±  36  20  ±  24  11  ±  15  8  ±  21  <  0.0001
Interventricular  septal  thickness  (mm)  18  ±  4  18  ±  4  15  ±  6  17  ±  4  0.32
Left  ventricular  end-diastolic  diameter  (mm)  47  ±  5  NA  NA  43  ±  12a 0.34
Mitral  valve  systolic  anterior  motion  49  (96)  13/34  (38)  10/34  (29)  6/41  (15)  <  0.0001
Missing  data 0  14/48  11/45  1/42
Mitral  insufﬁciency  grade
0  2  (4) 6/30  (20) 5/32  (16) 11/40  (28)
I  20  (39)  24/30  (80)  19/32  (59)  13/40  (32)
II  24  (47)  0  8/32  (25)  15/40  (38)  0.07
III  5  (10)  0  0  1/40  (2)
IV  0  0  0  0
Missing  data  0  18/48  13/45  2/42
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a Paired measurements available in 21 patients.
nfection  and  two  late  lead  infections,  all  requiring  device
xplantation.  Amiodarone-induced  thyroid  dysfunction  and
miodarone-induced  lung  disease  were  observed  in  12  and
wo  patients,  respectively.  Among  the  ICD  recipients,  three
eceived  inappropriate  shocks  due  to  lead  fractures  and  two
eceived  appropriate  shocks  for  sustained  ventricular  tachy-
ardia.
iscussion
he  very  late  effects  of  dual  chamber  pacing  for  drug-
efractory  HOCM  have  not  been  described.  Our  study
evealed  prominent  improvements  in  haemodynamic  and
linical  status  conferred  by  DDD  pacing  without  evidence
f  signiﬁcant  LV  remodelling.  However,  the  recent  practice
uidelines  issued  by  the  North  American  professional  soci-
ties  regarding  the  management  of  HOCM  have  assigned
DD  pacing  a  IIb  recommendation,  level  of  evidence  B,  for
atients  who  remain  symptomatic  despite  optimal  medi-
al  therapy  [12].  In  contrast,  myectomy  and  transcatheter
lcohol  septal  ablation  were  assigned  a  class  IIa  rec-
mmendation,  despite  having  never  been  scrutinized  in
ontrolled  studies.  This  recommendation  is  based  on  the
xperience  of  several  medical  institutions  that  found  both
herapies  highly  effective  in  alleviating  symptoms  and  LVOT
bstruction  [14—17].  The  superiority  of  surgical  myectomy
ompared  with  catheter  ablation  remains  unproven.  Sev-
ral  meta-analyses  failed  to  show  signiﬁcant  differences
etween  these  two  therapies  in  all-cause  mortality  or  risk
f  sustained  ventricular  tachyarrhythmias  [18,19].  The  only
igniﬁcant  difference  pertains  to  the  risk  of  AV  block  and
eed  for  pacemaker  implantation,  which  is  prominently
igher  after  catheter  ablation  (10—20%)  than  after  myec-
omy  (2%).  It  is  recommended  that  either  procedure  be
erformed  in  experienced  medical  centres  to  limit  the  risk  of
ajor  complications  and  to  obtain  optimal  and  reproducible
esults.
t
p
c
dIn  contrast,  the  implantation  of  a  DDD  pacemaker
emains  simple,  widely  available  and  associated  with  a  rela-
ively  low  rate  of  major  short-  and  long-term  complications.
s  opposed  to  the  other  treatments,  DDD  pacing  has  been
valuated  in  three  controlled  studies,  which  used  functional
ndpoints  and  yielded  conﬂicting  results.  In  a  small  pilot
tudy  from  the  Mayo  Clinic,  DDD  pacing  was  associated
ith  a  signiﬁcantly  smaller  LVOT  gradient  than  control  (AAI
acing),  although  it  conferred  no  signiﬁcant  clinical  ben-
ﬁt  [6].  A  similar  multicentre  study  comparing  DDD  with
AI  pacing  in  83  patients  observed  a  signiﬁcantly  greater
ecrease  in  LVOT  gradient  as  well  as  in  NYHA  functional
lass  and  quality  of  life  score  conferred  by  DDD  pacing,
lthough  it  had  no  signiﬁcant  effect  on  exercise  capac-
ty,  which  was  the  primary  study  endpoint  [7].  Finally,  in
nother  similarly  designed  study,  no  signiﬁcant  difference
as  observed  between  DDD  and  AAI  pacing  in  NYHA  func-
ional  class,  peak  exercise  O2 consumption  and  quality  of
ife  [8].
These  studies  suffered  from  several  limitations,  includ-
ng:  small  sample  sizes;  a  high  proportion  of  minimally
ymptomatic  patients,  which  limited  the  ability  to  measure
n  increase  in  functional  capacity;  suboptimal  primary  end-
oints,  such  as  duration  of  exercise  or  peak  exercise  O2
onsumption;  insufﬁcient  study  duration  to  reliably  evalu-
te  the  development  of  possible  ventricular  remodelling  by
acing;  and  the  suboptimal  use  of  the  implanted  devices  and
heir  programmable  features.
Furthermore,  the  importance  of  individually  optimizing
V  synchrony  in  the  left  heart  was  not  understood.  In
ractice,  the  beneﬁt  conferred  by  DDD  pacing  depends  on
wo  main  conditions:  complete  ventricular  capture  from  the
V  apex,  which  allows  the  complete  reversal  of  the  LV  acti-
ation  sequence  and  alleviation  of  the  dynamic  obstacle
o  systolic  ejection  by  delaying  septal  contraction;  and  the
reservation  of  optimal  LV  ﬁlling  by  left  atrial  contraction,  a
ritical  event  in  cardiac  disorders  characterized  by  diastolic
ysfunction.  Optimal  AV  synchrony  is,  therefore,  critical  and
Long-term  DDD  pacing  for  HOCM  
Figure 4. A. Peak left ventricular outﬂow tract (LVOT) gradi-
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large  Canadian  registry  [22].ent. B. Left ventricular ejection fraction. C. Interventricular septal
thickness.
mandates  the  programming  of  the  longest  AV  delay  associ-
ated  with  complete  ventricular  capture.
In  the  present  study,  we  sought  to  reach  optimal  AV  syn-
chrony  in  all  patients.  When  baseline  programming  did  not
allow  the  achievement  of  the  two  conditions  mentioned  ear-
lier,  we  intensiﬁed  the  drug  treatment  in  order  to  lengthen
the  intrinsic  PR  interval  and  optimize  LV  ﬁlling.  At  the
end  of  follow-up,  83%  of  patients  were  treated  with  AV
node  conduction-slowing  drugs,  such  as  a  beta-adrenergic
blocker,  verapamil  or  both,  and  seven  patients  underwent
b
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blation  of  the  AV  junction  after  unsuccessful  intensiﬁcation
f  medical  therapy.  Finally,  21  patients  who  presented  with
rominent  intra-atrial  conduction  disturbances  and  delayed
eft  atrial  contraction  received  a  biatrial  DDD  pacemaker
o  resynchronize  the  atria  [13,20]. Individual  optimization
f  left  AV  synchrony  possibly  explains  the  greater  decline
n  LVOT  gradient  observed  in  this  study  compared  with
thers.
In  this  study,  pacing  effectively  alleviated  symptoms,
s  NYHA  functional  class,  angina  pectoris,  syncope  and
resyncope  all  regressed  signiﬁcantly  during  follow-up  and
emained  stable  over  time  in  the  majority  of  patients.
esides  the  functional  improvement,  dynamic  obstruction
as  clearly  alleviated.  It  is  noteworthy  that  the  improve-
ent  in  echocardiographic  measurements,  the  decrease  in
radient  and  the  suppression  of  mitral  valve  systolic  ante-
ior  motion  in  particular,  occurred  progressively  throughout
he  follow-up.
As  expected,  RV  apical  pacing  depressed  LV  systolic  func-
ion,  although  the  effect  was  modest,  as  LVEF  decreased
rom  63.5  ±  7.5%  before  implantation  of  the  pacemakers  to
6  ±  9%  at  last  follow-up.  Among  patients  whose  ventricular
ize  was  measured  serially,  LVEF  decreased  without  concomi-
ant  ventricular  dilatation.  Except  for  the  two  patients  who
eveloped  refractory  heart  failure  and  underwent  cardiac
ransplantation  after  8  and  12  years  of  pacing,  we  observed
o  evolution  toward  LV  systolic  dysfunction  caused  by  per-
anent  pacing.
The  results  of  this  study  are  encouraging.  Long-term  pac-
ng  for  HOCM  has  been  the  subject  of  scarce  reports.  An
bservational  study  of  50  patients  in  NYHA  functional  classes
II  and  IV,  over  a  shorter  follow-up  of  5  ±  3  years  on  average,
eported  similar  clinical  results  (decrease  in  NYHA  func-
ional  class,  increase  in  distance  covered  during  hall  walk
est  and  improvement  in  quality  of  life)  as  well  as  echocar-
iographic  observations  (decrease  in  resting  gradient  from
6  ±  29  mmHg  to  28  ±  24  mmHg  at  the  end  of  follow-up  and
ecrease  in  LVEF  after  pacing  without  LV  dilatation)  [9].  Sim-
lar  results  were  observed  in  another  study  of  18  patients
ollowed  for  a mean  of  4.1  years  [10].  The  clinical  bene-
ts  observed  in  our  study  were  maintained  over  a  period
f  11.5  years  on  average.  While  the  90%  survival  at  5  years
as  close  to  that  observed  after  myectomy  in  large  clinical
egistries,  it  decreased  to  65%  at  10  years.  The  mean  age  of
he  patients  included  in  our  study  was  59  years,  considerably
lder  than  the  mean  age  of  45  years  of  the  patients  included
n  surgical  series.  Actually,  our  data  can  be  compared  to
hose  of  a  prospective  registry  from  the  Mayo  Clinic  that
ncluded  544  consecutive  patients  presenting  with  asymp-
omatic  or  minimally  symptomatic  HOCM  with  the  same
ean  age  (59  ±  16  years)  as  that  of  our  population  [21].  They
bserved  a 10-year  survival  rate  of  69.3%,  close  to  that  of  the
eneral  population  in  the  USA.  However,  in  patients  with  a
igh  gradient  (Vmax >  4  m/s),  the  survival  rate  was  53%,  con-
istent  with  the  rate  observed  in  our  patient  sample.  The
on-cardiovascular  death  rate  was  higher  in  our  study  (73%
s  46%),  perhaps  reﬂecting  more  prevalent  and  more  severe
o-morbidity.  Nearly  similar  data  were  reported  in  anotherIn  patients  with  intra-atrial  conduction  block,  we  used
iatrial  synchronous  DDD  pacing  to  further  optimize  AV  syn-
hrony  in  the  left  heart.  However,  because  of  a  high  rate
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f  postoperative  complications,  mainly  coronary  sinus  lead
islodgment,  the  risk-beneﬁt  ratio  of  this  practice  is  unclear.
Finally,  the  role  of  ICD  in  HOCM  remains  controversial
12].  In  this  historical  series,  few  patients  received  devices
ith  ICD  function,  including  four  patients  at  initial  implant
or  secondary  prevention,  two  patients  who  underwent
evice  upgrade  after  experiencing  life-threatening  ventri-
ular  tachyarrhythmias  and  four  patients  who  had  primary
revention  indications  [12]  at  the  time  of  device  replace-
ent.  In  the  overall  population,  4/10  cardiovascular  deaths
ere  sudden  and  occurred  in  recipients  of  devices  without
CD  function.  These  observations  could  support  wider  indica-
ions  of  devices  with  ICD  function  in  HOCM  patients  treated
y  DDD  pacing.
tudy limitations
his  study  has  the  intrinsic  limitations  of  an  observational
etrospective  single-centre  study.  The  more  than  20-year
ollow-up  explains  missing  data  with  a  small  proportion  of
aired  data  for  LV  dimensions  as  well  as  the  loss  of  patient
ollow-ups.
In  ﬁve  patients,  LV  obstruction  was  not  present  at
est  but  was  provoked  by  nitroglycerine,  which  is  no
onger  recognized  as  a  physiological  manoeuvre.  No  exercise
chocardiography  was  performed  in  this  historical  series.
onclusions
ur  study  illustrates  the  beneﬁcial  effects  of  very  long-term
DD  pacing  in  patients  with  symptomatic  HOCM  refrac-
ory  to  medical  therapy.  The  beneﬁt  was  both  clinical  and
aemodynamic,  with  a  clear  decrease  in  the  LVOT  gradi-
nt.  The  effects  appeared  within  a  few  weeks  of  pacing  and
ere  maintained  or  even  enhanced  over  more  than  20  years
f  follow-up.  The  place  of  this  easily  accessible  and  rela-
ively  safe  treatment  should  be  reconsidered,  in  particular
or  patients  of  advanced  age  or  in  patients  with  indication
or  an  ICD,  although  its  risk-beneﬁt  ratio  should  be  ﬁrst  pre-
isely  examined  in  a  multicentre  study,  over  a  sufﬁciently
ong  period  of  observation.
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